MEMANTINE HYDROCHLORIDE by Hikma is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer’s disease. Approved for moderate to severe dementia of the alzheimer’s type. First approved in 2020.
Drug data last refreshed 21h ago
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Worked on MEMANTINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.